

# Young Shin Song

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9385165/publications.pdf>

Version: 2024-02-01

31  
papers

1,318  
citations

471061

17  
h-index

414034

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1791  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. <i>PLoS Genetics</i> , 2016, 12, e1006239.	1.5	265
2	Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. <i>Nature Communications</i> , 2019, 10, 2764.	5.8	166
3	Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. <i>Cancer</i> , 2016, 122, 1370-1379.	2.0	147
4	Effects of Coexistent <i>BRAF</i> <sup>V600E</sup> and <i>TERT</i> Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. <i>Thyroid</i> , 2017, 27, 651-660.	2.4	122
5	Mutation Profile of Well-Differentiated Thyroid Cancer in Asians. <i>Endocrinology and Metabolism</i> , 2015, 30, 252.	1.3	66
6	<i>NTRK</i> and <i>RET</i> fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	62
7	Interaction of <i>BRAF</i> -induced ETS factors with mutant <i>TERT</i> promoter in papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 629-641.	1.6	60
8	Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of Tj ETQq0 0 0 rgBT Overlock 15 Tf 50 45)	1.6	50
9	<i>CXCL16</i> positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer. <i>Scientific Reports</i> , 2019, 9, 13288.	1.6	46
10	Genomic Characterization of Differentiated Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2019, 34, 1.	1.3	37
11	Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro). <i>Endocrinology and Metabolism</i> , 2018, 33, 278.	1.3	35
12	Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and <i>CXCL8</i> Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 414-425.	3.2	28
13	Loss-of-function of <i>IFT88</i> determines metabolic phenotypes in thyroid cancer. <i>Oncogene</i> , 2018, 37, 4455-4474.	2.6	27
14	Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. <i>European Journal of Endocrinology</i> , 2017, 177, 465-473.	1.9	26
15	A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma ( <i>ERR</i> <sup>γ</sup> ), DN200434, A Booster of <i>NIS</i> in Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5069-5081.	3.2	24
16	Association between <i>MA</i> ™s disease and thyroid diseases: a nested case-control study. <i>Scientific Reports</i> , 2020, 10, 18224.	1.6	24
17	Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2018, 28, 1468-1478.	2.4	21
18	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. <i>Endocrinology and Metabolism</i> , 2020, 35, 44.	1.3	21

#	ARTICLE	IF	CITATIONS
19	Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma. <i>Cancers</i> , 2020, 12, 1345.	1.7	12
20	DEHP Down-Regulates Tshr Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption. <i>Endocrinology and Metabolism</i> , 2021, 36, 447-454.	1.3	12
21	Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity. <i>Yonsei Medical Journal</i> , 2016, 57, 795.	0.9	10
22	Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E. <i>Endocrinology and Metabolism</i> , 2020, 35, 515-525.	1.3	10
23	Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study. <i>Diagnostics</i> , 2021, 11, 329.	1.3	9
24	Increased expression of thyroid hormone receptor alpha and estrogen receptor alpha in breast cancer associated with thyroid cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1316-1323.	0.5	9
25	Association between SSNHL and Thyroid Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8419.	1.2	6
26	Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis. <i>Journal of Korean Medical Science</i> , 2017, 32, 1721.	1.1	4
27	Star-Shaped Intense Uptake of <sup>131</sup> I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq. <i>Endocrinology and Metabolism</i> , 2018, 33, 228.	1.3	4
28	Evaluation of the relationship between previous statin use and thyroid cancer using Korean National Health Insurance Service-Health Screening Cohort data. <i>Scientific Reports</i> , 2021, 11, 7912.	1.6	3
29	Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort. <i>Endocrinology and Metabolism</i> , 2018, 33, 395.	1.3	2
30	Screening Leads to Overestimated Associations of Thyroid Dysfunction and Thyroiditis with Thyroid Cancer Risk. <i>Cancers</i> , 2021, 13, 5385.	1.7	2
31	Expression of Sodium-Iodide Symporter Depending on Mutational Status and Lymphocytic Thyroiditis in Papillary Thyroid Carcinoma. <i>International Journal of Thyroidology</i> , 2018, 11, 152.	0.1	1